Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis c virus (genotypes 1 and 4) infection

Journal of Pediatric Gastroenterology and Nutrition

Volumn 57, Issue 6, 2013, Pages 694-699

  Wiåniewska Ligier, Malgorzata ^a   Pawłowska, Malgorzata ^b   Pilarczyk, Malgorzata ^b   Halota, Waldemar ^b   Woåniakowska Gȩsicka, Teresa ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Children; Chronic hepatitis C; Pegylated interferon a2b; Ribavirin; Virologic response

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TREATMENT RESPONSE;

HEPATITIS C VIRUS;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETREATMENT; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84889654562     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182a7d91e     Document Type: Article

References (25)

1. Juszczyk J. Fifteen years of investigations on hepatitis C virus in Poland. Przegl Epidemiol 2005;59:373-84.
2. National Institutes of Health. Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26 (3 suppl 1): 2S-10S.
3. European Association for the Study of the Liver. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999;30:956-61.
4. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebocontrolled trial. Ann Intern Med 1995;123:897-903.
5. Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: Clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275-80. (Pubitemid 36169661)
6. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008;47:836-43. (Pubitemid 351449675)
7. Jara P, Hierro L. Treatment of hepatitis C in children. Expert Rev Gastroenterol Hepatol 2010;4:51-61.
8. Barshes NR, Udell IW, Lee TC, et al. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl 2006;12: 1119-23. (Pubitemid 44063787)
9. Grace MJ, Cutler DL, Bordens RW. Pegylated IFNs for chronic hepatitis C: an update. Expert Opin Drug Deliv 2005;2:219-26. (Pubitemid 41130879)
10. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
11. Halota W, Flisiak R, Boron-Kaczmarska A, et al. Standards of hepatitis C treatment. Recommendations of Polish Group of Experts. Przegl Epidemiol 2012;66:83-8.
12. Gabriel A, Mietkiewski J, Zio?kowski A. Current morphological classification of chronic liver inflammation: its merits and problems. Pol J Pathol 1999;50 (4 suppl 1):5-11.
13. Olson M, Jacobson IM. Role of the nurse practitioner in the management of patients with chronic hepatitis C. J Am Acad Nurs Pract 2011;23:410-20.
14. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501-7.
15. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-8.
16. Sokal EM, Bourgois A, Stephenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010;52:827-31.
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: 958-65. (Pubitemid 32913521)
18. AmanW, Mousa S, Shiha G, et al. Current status and future directions in the management of chronic hepatitis C. Virol J 2012;9:57.
19. European Association for the Study of the Liver. Clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55: 245-64.
20. Jara P, Hierro L, de la Vega A, et al. Efficacy and safety of peginterferonalpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8.
21. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593-601.
22. Davis GL,Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52. (Pubitemid 37052151)
23. Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2002;11:515-28. (Pubitemid 34450122)
24. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26: 780-5. (Pubitemid 27392374)
25. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.